Pancreatic Cancer Research

ResearcherUniversity of MiamiNo recent work listed

Albert Craig Lockhart

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1256-6709; OpenAlex author ID A5064343766; NIH RePORTER profile ID 3047483. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
1
Labs led
1
Collaborators
34
Papers, trials and grants by year

2012: 1 paper · 2013: 4 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper, 1 grant · 2021: none · 2022: 1 paper · 2023: 1 paper

Papers 10

  1. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… Co-author DOI 10.1158/1078-0432.ccr-23-2993↗
  2. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Co-author DOI 10.1158/1078-0432.ccr-22-0308↗
  3. Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2019.11.06↗
  4. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-16-1121↗
  5. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/s1470-2045(16)00078-4↗
  6. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s10637-012-9866-y↗
  7. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of c… Co-author DOI 10.1021/mp3005353↗
  8. Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. Co-author DOI 10.1186/1479-5876-11-206↗
  9. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. Co-author DOI 10.1371/journal.pone.0077243↗
  10. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. Co-author DOI 10.6092/1590-8577/913↗

Grants 1

  1. Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrea Wang‐Gillam · 9 shared papers, 1 shared grant, 2012–2023 · strength 0.84
  2. David G DeNardo · 5 shared papers, 1 shared grant, 2013–2023 · strength 0.64
  3. William G. Hawkins · 5 shared papers, 1 shared grant, 2013–2023 · strength 0.60
  4. Kian‐Huat Lim · 5 shared papers, 2016–2023 · strength 0.46
  5. Katrina Sophia Pedersen · 3 shared papers, 2020–2023 · strength 0.34
  6. Feng Gao · 4 shared papers, 2012–2023 · strength 0.30
  7. Ryan C Fields · 1 shared paper, 1 shared grant, 2016–2020 · strength 0.30
  8. Robert R. McWilliams · 3 shared papers, 2012–2023 · strength 0.27
  9. Graham A. Colditz · 1 shared grant, 2020 · strength 0.25
  10. William E. Gillanders · 1 shared grant, 2020 · strength 0.25
  11. Brett H. Herzog · 2 shared papers, 2022–2023 · strength 0.24
  12. Jad I. Belle · 2 shared papers, 2022–2023 · strength 0.24
  13. David C. Linehan · 3 shared papers, 2012–2016 · strength 0.10
  14. Patrick M. Grierson · 1 shared paper, 2020 · strength 0.10
  15. Andrea S. Teague · 1 shared paper, 2020 · strength 0.10
  16. Lingling Du · 1 shared paper, 2020 · strength 0.10
  17. Hongmei Jiang · 1 shared paper, 2017 · strength 0.07
  18. Daoxiang Zhang · 1 shared paper, 2017 · strength 0.07
  19. Parvin F. Peddi · 2 shared papers, 2012–2013 · strength 0.06
  20. Steven M. Sorscher · 2 shared papers, 2012–2013 · strength 0.06
  21. Timothy M. Nywening · 1 shared paper, 2016 · strength 0.04
  22. Kathryn Jane Fowler · 1 shared paper, 2016 · strength 0.04
  23. Dominic E. Sanford · 1 shared paper, 2016 · strength 0.04
  24. Roheena Z. Panni · 1 shared paper, 2016 · strength 0.04
  25. Steven M. Strasberg · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.